FINANCINGS
Aeterna Zentaris Inc. entered an at-market issuance sales agreement with MLV & Co. LLC.
Agile Therapeutics Inc. filed to raise up to $65 million in an IPO.
Celator Pharmaceuticals Inc. entered a $15 million loan agreement with Hercules Technology Growth Capital Inc.
Chase Pharmaceuticals Corp. raised $21 million in a series B financing round.
Imaginab Inc. completed a $21 million series B financing round.
Invivo Therapeutics Holdings Corp. closed a public offering for gross proceeds of approximately $16.1 million.
Gemmus Pharma Inc. said it closed a $3.3 million series B financing round.
Marinus Pharmaceuticals Inc. filed to raise up to $63 million in an IPO.
Radius Health Inc. postponed its IPO citing poor market conditions.
Sorrento Therapeutics Inc. expects to generate $25 million in gross proceeds from a public offering.
Sorbent Therapeutics Inc. said it closed a $6.5 million tranche of a $15 million series D financing.
ZS Pharma Inc. is seeking to raise up to $86 million from an IPO.
DEALS
Allergan Inc. has rejected the unsolicited April 22 acquisition proposal from Valeant Pharmaceuticals International Inc.
Aslan Pharmaceuticals Pte Ltd. signed an agreement with CSL Ltd. to develop an anti-IL-13 receptor monoclonal antibody, CSL334, for severe to moderate asthma.
Bristol-Myers Squibb Co. is testing PD-1 checkpoint inhibitor nivolumab in non-small-cell lung cancer with Celldex Therapeutics Inc.'s CD27-targeting varlilumab.
Jubilant Biosys Ltd. and Orion Corp. are collaborating to discover small-molecule inhibitors in the neuroscience therapeutic area.
Mabvax Therapeutics Inc., a privately held cancer immuno-therapy company, is merging with publicly traded Telik Inc.
Medimmune is testing its anti-PDL-1 immune checkpoint inhibitor, MEDI4736, in combination with Incyte Inc.'s oral indoleamine dioxygenase-1 inhibitor.
Merck & Co. Inc. signed a deal to sell nine of its ophthalmic products to Japan-based Santen Pharmaceutical Co. Ltd.
Prometic Life Sciences Inc. increased its ownership in Nantpro LLC.
Shire plc is acquiring Lumena Pharmaceuticals Inc. for $260 million up front plus undisclosed milestones.
Riemser Pharma GmbH acquired Keocyt, which markets pharmaceutical products to treat rare diseases.
Zalicus Inc. said Horizon Discovery Group will acquire its combination high-throughput screening platform and related assets for $8 million.
. . . AND MORE
Abeona Therapeutics has been granted FDA orphan drug designations for its lead investigational therapies for treatment of Sanfilippo syndromes A and B.
ALK-Abello A/S said partner Merck & Co. Inc. launched ragweed allergy immunotherapy tablet Ragwitek in Canada.
Beryllium has finalized its consolidation of assets from Emerald Bio and Decode Genetics and emerged as a drug discovery company.
Daiichi Sankyo Co. Ltd. discontinued a phase III trial for nimotuzumab after four treatment-related deaths were observed, all in the nimotuzumab arm.
Health Canada has suspended the establishment license of Biolyse Pharma Corp.'s facility in St. Catharines, Ontario, because of concerns with the manufacturing process.
Merck & Co. Inc. said the FDA approved Zontivity (vorapaxar) to reduce thrombotic cardiovascular events in patients with a history of heart attack or with peripheral arterial disease.
Provectus Biopharmaceuticals Inc. said its shares have been approved for listing on the NYSE MKT.